Article
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.
Blood cancer discovery - 1 Mar 2021
Alotaibi Ahmad S, Yilmaz Musa, Kanagal-Shamanna Rashmi, Loghavi Sanam, Kadia Tapan M, DiNardo Courtney D, Borthakur Gautam, Konopleva Marina, Pierce Sherry A, Wang Sa A, Tang Guilin, Guerra Veronica, Samra Bachar, Pemmaraju Naveen, Jabbour Elias, Short Nicholas J, Issa Ghayas C, Ohanian Maro, Garcia-Manero Guillermo, Bhalla Kapil N, Patel Keyur P, Takahashi Koichi, Andreeff Michael, Cortes Jorge E, Kantarjian Hagop M, Ravandi Farhad, Daver Naval
Abstract excerpt
Despite promising results with FLT3 inhibitors (FLT3i), response durations remain short. We studied pretreatment and relapse bone marrow samples from patients with FLT3-mutated AML treated with FLT3i-based therapies (secondary resistance cohort), and pretreatment bone marrow samples from patients with no response to FLT3i-based therapies (primary resistance cohort). Targeted next generation sequencing at relapse...
Topics
- Drug Resistance, Neoplasm
- High-Throughput Nucleotide Sequencing
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Protein Kinase Inhibitors
- fms-Like Tyrosine Kinase 3